Specifically, in gastrointestinal tumors, high PD-L1 expression on CTCs at baseline might serve as a predictor to screen patients for PD-1/PD-L1 blockade therapies, and measuring the dynamic changes in CTCs could monitor the therapeutic response [19]. The gene discussed is CD274; the disease is digestive system neoplasm.